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Abstract 
Protein misfolding underlies the pathology of a large number of human disorders, many of which are age-
related. An exception to this is preeclampsia, a leading cause of pregnancy-associated morbidity and 
mortality in which misfolded proteins accumulate in body fluids and the placenta. We demonstrate that 
pregnancy zone protein (PZP), which is dramatically elevated in maternal plasma during pregnancy, 
efficiently inhibits in vitro the aggregation of misfolded proteins including the amyloid beta peptide (Aβ) 
that is implicated in preeclampsia as well as with Alzheimer’s disease. The mechanism by which this 
inhibition occurs involves the formation of stable complexes between PZP and monomeric Aβ or small 
soluble Aβ oligomers formed early in the aggregation pathway. The chaperone activity of PZP is more 
efficient than that of the closely-related protein alpha-2-macroglobulin (α2M), although, the chaperone 
activity of α2M is enhanced by inducing its dissociation into PZP-like dimers. By immunohistochemistry 
analysis, PZP is found primarily in extravillous trophoblast in the placenta. In severe preeclampsia, PZP-
positive extravillous trophoblasts are adjacent to extracellular plaques containing Aβ, but PZP is not 
abundant within extracellular plaques. Our data support the conclusion that the upregulation of PZP 
during pregnancy represents a major maternal adaptation that helps to maintain extracellular 
proteostasis during gestation in humans. We propose that overwhelming or disrupting the chaperone 
function of PZP could underlie the accumulation of misfolded proteins in vivo.  Attempts to characterise 
extracellular proteostasis in pregnancy is a new frontier with potentially broad-reaching significance for 
understanding disease-related protein misfolding. 
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Significance Statement 
Pregnancy is a unique physiological state involving biological stresses that promote protein damage 
(misfolding) within the maternal body. Currently, little is known regarding how the maternal body copes 
with elevated protein misfolding in pregnancy. This is important because the accumulation of misfolded 
proteins underlies many human disorders including preeclampsia, a serious complication of pregnancy. 
In this study we show that pregnancy zone protein (PZP) efficiently inhibits the aggregation of misfolded 
proteins including the amyloid beta peptide, which forms plaques in preeclampsia and in Alzheimer’s 
disease. We propose that upregulation of PZP is a major maternal adaptation that helps to maintain 
protein homeostasis during pregnancy. Moreover, pregnancy-independent upregulation of PZP indicates 
that its chaperone function could be broadly important in humans.  
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Introduction 
Normal healthy pregnancy is a state in which physiological stresses that are capable of inducing protein 
misfolding are considerably heightened. In part, these stresses are the consequence of a systemic 
inflammatory response involving the generation of reactive oxygen species (1), which contribute to a 
measurable increase in the oxidation of maternal plasma proteins (2). The placenta, which is the interface 
between the mother and the developing fetus, is another major contributor to the generation of reactive 
oxygen species due to its high level of metabolic activity (reviewed in(3). Additionally, body temperature 
is slightly, but chronically, elevated during pregnancy (4) and a tremendous increase in blood volume 
promotes shear stress (5, 6). As pregnancy advances, the feto-placental unit produces many new 
secreted proteins that all need to be trafficked and ultimately cleared by maternal organs under these 
physically unfavourable conditions. Remarkably, virtually nothing is known regarding the way that the 
maternal body adapts to handle the unique protein homeostasis (proteostasis) challenges of pregnancy.  
 
Aberrant accumulation of misfolded proteins in extracellular fluids underlies the pathology of a large 
number of age-related disorders including Alzheimer’s disease, macular degeneration, arthritis and 
atherosclerosis (7). Aside from these age-related disorders, misfolded proteins have been shown to 
accumulate in the urine, serum and the placenta of women with preeclampsia (8-12), a leading cause of 
pregnancy-related morbidity and mortality. The broad-spectrum of disorders known to involve protein 
misfolding highlight the fact that proteins are vulnerable to misfolding as a consequence of  genetic and 
environmental changes (13), including pressures that occur as a normal part of pregnancy in mammals. 
A collapse in the proteostasis network is recognised as a key event associated with aging and ultimately 
death (14). Intuitively, in order to cope with pregnancy-associated physiological stresses, the functions 
of the pregnancy-associated proteostasis network will be critically important.  
 
A small number of normally secreted proteins including clusterin, haptoglobin and alpha-2-macroglobulin 
(α2M) have been shown to stabilise and inhibit the aggregation of misfolded proteins (reviewed in(15). 
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Collectively these proteins are known as extracellular chaperones. Levels of known extracellular 
chaperones do not increase significantly in maternal blood during normal healthy pregnancy (16-19). 
Therefore it is conceivable that one or more pregnancy-associated proteins, which are upregulated during 
gestation, play a major role in stabilising misfolded proteins. Of the numerous changes that occur in the 
maternal plasma proteome during pregnancy, one of the most dramatic is the increase in pregnancy 
zone protein (PZP) levels. The concentration of PZP in human blood plasma is normally <0.03 mg/ml, 
but by 30 weeks of gestation PZP levels can reach up to 1.5-3 mg/mL in some individuals (20). It is 
currently unclear why the body makes this tremendous investment in the upregulation of PZP in 
pregnancy when levels of α2M, a closely related α-macroglobulin (αM) family member are constitutively 
high in human blood plasma  (~1.5-2 mg/ml; (21)).  
 
In humans α2M (a tetramer) and PZP (a dimer) share 71% sequence homology (22) and are historically 
best known as protease inhibitors. However, compared to α2M, PZP is relatively inefficient at performing 
this activity and PZP-protease interactions have only been described for a restricted number of proteases 
substrates in vitro (23-27). In more recent years the multifunctional nature of α2M has become apparent 
(reviewed in(28). For example, reaction of α2M with hypochlorite, an oxidant that is produced during 
inflammation, induces the dissociation of the native α2M tetramer into dimers (29, 30). The hypochlorite-
induced dissociation of α2M into dimers results in a loss of the protease trapping activity of α2M (30), but 
a potent activation of its chaperone activity (29). Compared with the native α2M tetramer, α2M dimers 
preferentially bind not only to misfolded proteins but also to a variety of other ligands, including signalling 
molecules (29, 31, 32). Given that PZP is normally a dimer in biological fluids, we hypothesised that PZP 
could be an efficient chaperone that stabilises misfolded proteins in a manner similar to dimeric α2M. In 
the present study we examined the effect of purified PZP on the fibrillar aggregation of the Aβ peptide 
associated with Alzheimer’s disease, which has also been implicated in pathological changes occurring 
in the placenta in preeclampsia (8). To increase the physiological relevance of our studies we investigated 
the aggregation propensity of proteins in pregnancy plasma in situ and determined the localisation of 
PZP in placental tissue from women with preeclampsia and of control women matched by gestational 
age. 
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Results 
Pregnant women with low PZP levels do not compensate by upregulating α2M 
PZP was purified from pooled human pregnancy plasma as described previously (33). When analysed 
by native Western blotting, purified PZP migrated to the same position as PZP in heparin-treated human 
pregnancy plasma when probed by native Western blot analysis (Fig. 1A). This was important to assess 
because purified PZP has a tendency to aggregate during extended storage, a process that has 
functional consequences (34). The polyclonal anti-PZP antibody used in these experiments did not react 
with highly purified α2M, verifying its specificity for PZP (Fig. 1A). By native gel analysis the migration of 
purified PZP was faster than that of native and transformed α2M (α2M*; a compact tetrameric form 
generated by reaction of the α2M thioester bond), but comparable to that of hypochlorite-liberated α2M 
dimers (Fig. 1B). The latter migrated in a more diffuse manner compared to PZP, consistent with a 
heterogeneous population of species differing slightly in physical properties that are present in the 
hypochlorite-modified α2M preparation (29). The results of native Western blot analyses indicated that 
there was marked variation in plasma levels of PZP between individuals matched for gestational age (36 
weeks), while plasma levels of α2M were comparatively similar in all of the samples examined (Fig. 1C). 
Densitometric analysis of α2M and PZP (collectively referred to as αMs) in pregnancy plasma indicated 
that there is only a weak correlation between PZP and α2M levels (R2 = 0.2236) (Fig. 1D). The latter 
result supports the conclusion that individuals with low PZP in pregnancy do not compensate by 
upregulating α2M. 
 
PZP inhibits Aβ1-42  amyloid formation more efficiently than native α2M 
The ability of purified PZP to inhibit the fibrillar aggregation of the 42-residue isoform of the Aβ peptide 
(Aβ1-42) was assessed using the well-established thioflavin T assay (ThT). Under the conditions used, 
Aβ1-42 aggregated over a period of approximately 10 h following a short lag phase of approximately 1 h 
(Fig 2A). Co-incubation of Aβ1-42 with PZP both extended the lag phase and reduced the rate of fibril 
formation in a dose-dependent manner (Fig. 2A). Compared to the native α2M tetramer, PZP more 
efficiently inhibited the ThT fluorescence associated with the formation of amyloid fibrils of Aβ1-42 except 
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at the lowest ratio of αM-to-Aβ1-42 tested (i.e. 1 molecule of α2M or PZP-to-80 molecules of Aβ1-42) (Fig 
2A). In the latter case, both native α2M and PZP reduced the initial rate of fibril formation, but did not 
significantly reduce the overall ThT fluorescence at the conclusion of the assay. Consistent with our 
previous report (29), α2M dimers (generated by pre-treatment with hypochlorite and purified by size 
exclusion chromatography) inhibited Aβ1-42-associated ThT fluorescence far more efficiently than the 
native α2M tetramer in all experiments (Fig. 2A). Comparatively, the effect of PZP was less than that of 
the hypochlorite-modified α2M dimer preparation, except at the highest ratio of αM-to-Aβ1-42 tested (i.e. 1 
molecule of PZP or α2M dimer-to-20 molecules of Aβ1-42) when the two dimeric proteins had similar 
effects. The results of a bisANS assay suggest that surfaced exposed hydrophobicity underpins the 
chaperone activity of αMs (Fig. 2B). Consistent with the results of prior studies (35, 36), our data show 
that native PZP is relatively more hydrophobic than native α2M. In the case of the hypochlorite-modified 
α2M dimer, the dramatically elevated surface hydrophobicity is the combined effect of the dissociation of 
the normally buried hydrophobic interface of non-covalently associated α2M dimers and of hypochlorite-
induced perturbations to the secondary structure of α2M (29). Considering that tetrameric α2M (720 kDa) 
and PZP (360 kDa) are both comprised of monomeric αM subunits (180 kDa), comparison of native α2M 
and PZP at equivalent molar ratios (as in Fig. 2A) is biased in terms of total αM subunits number (and 
mass) in favour of α2M. Therefore, we re-evaluated the ability of native α2M and PZP to inhibit Aβ1-42-
associated ThT fluorescence under conditions where the total number of αM subunits were equivalent 
(Fig. 2C). The latter experiment demonstrates that on a subunit basis the ability of native PZP to inhibit 
Aβ1-42-associated ThT fluorescence is substantially greater than that of native α2M in vitro.  
 
Qualitative analysis by transmission electron microscopy (TEM) indicated that aggregation of Aβ1-42 alone 
resulted in assemblies with morphologies consistent with amyloid fibrils (Fig. 3A). The relative abundance 
of fibrillar material observed correlated closely with the results of the ThT assays whereby co-incubation 
with the native α2M tetramer appeared less efficient at inhibiting fibril formation compared to PZP and the 
hypochlorite-modified α2M dimer, respectively (Fig. 3A). In samples containing Aβ1-42 and PZP, small non-
fibrillar aggregates that were relatively uniform in size and morphology were present. Interestingly, 
quantification of the concentration of soluble Aβ1-42 at the conclusion of the assay indicated that under 
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the conditions used, co-incubation with PZP or hypochlorite-modified α2M dimers retained a similar 
amount of Aβ1-42 in the soluble fraction (Fig. 3B). Corresponding samples containing Aβ1-42 co-incubated 
with native α2M, however, contained less than 10% of the levels of soluble Aβ1-42 present after co-
incubation with dimeric αMs (Fig. 3B). Following incubation of Aβ1-42 in the absence of any of the proteins 
at 37°C soluble Aβ1-42 could not be detected. 
 
PZP forms stable complexes with Aβ1-42   
We have previously reported that monomeric Aβ1-42 and/or small soluble species formed early in the 
aggregation pathway bind to hypochlorite-modified α2M but do not bind to the native α2M tetramer in vitro 
(29). Consistent with this report, when Hilyte-labelled Aβ1-42 was co-incubated with native α2M and then 
subjected to native gel electrophoresis, negligible co-migration of labelled Aβ1-42 with the α2M tetramer 
was detected (Fig. 4A). In contrast, when Hilyte-labelled Aβ1-42 was co-incubated with either hypochlorite-
modified α2M or PZP, significant levels of labelled Aβ1-42 co-migrating with these proteins during native 
gel electrophoresis were detected in both cases (Fig. 4A).  The formation of stable PZP-Aβ1-42 complexes 
was confirmed using a streptavidin-biotin pull-down assay, and demonstrated that PZP (180 kDa) co-
eluted with biotinylated Aβ1-42 at much greater levels than was the case for the non-specific binding of 
PZP to the beads alone (Fig. 4B).  Although monomeric Aβ1-42 could not be detected co-migrating with 
the native α2M tetramer (Fig. 4A), when analysed by native Western blotting, co-migration of Aβ1-42  and 
the native α2M tetramer was detected if the peptide was pre-incubated to induce its aggregation (SI 
Appendix Fig. S1).  
 
PZP inhibits heat-induced protein aggregation  
Considering that the accumulation of misfolded proteins in preeclampsia is not limited to Aβ (8-12), we 
examined the effect of PZP on the heat-induced aggregation of citrate synthase (CS), a model protein 
used to form amorphous protein aggregates. Heating of CS at 43°C induced its aggregation over a period 
of approximately 5 h as measured by the absorbance of the solution at 595 nm (i.e. turbidity), and co-
incubation of CS with PZP reduced the level of CS aggregation in a dose-dependent manner (Fig. 5A). 
At a 1:2.5 molar ratio (PZP-to-CS), the inhibitory effect of PZP on the aggregation of CS was significantly 
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greater than the comparable effect of native α2M at the conclusion of the assay (Fig. 5A). For clarity, 
kinetic curves (Fig. 5Ai) and statistical analysis of end-point absorbance values (Fig. 5Aii) are presented 
separately. To examine the possibility that monomeric αMs also stabilise misfolded proteins in vitro, the 
chaperone activity of native α2M, PZP and monomeric Escherichia coli α2M (ECAM) were directly 
compared using heat denatured creatine phosphokinase (CPK; another commonly used model protein 
that forms amorphous aggregates). The results of these assays indicate that, like tetrameric α2M, 
monomeric Escherichia coli α2M (ECAM) is relatively ineffective in suppressing heat-induced CPK 
aggregation compared to PZP (Fig. 5B). We have previously shown that hypochlorite-modified α2M 
dimers more efficiently inhibit amorphous protein aggregation compared to the native α2M tetramer (29), 
the available evidence therefore supports the conclusion that dimeric quaternary structure is important 
for the chaperone activity of the αMs. To verify that purified ECAM did not aberrantly form higher order 
assemblies such as dimers or tetramers, a native gel showing the migration of purified ECAM compared 
to reduced monomeric α2M is provided in SI Appendix Fig. S2.  
 
Using conditions that are known to induce plasma protein precipitation (37, 38), the aggregation 
propensities of plasma proteins from preeclamptic women or women experiencing uncomplicated 
pregnancy (control) were examined in situ. The two types of pooled plasma samples examined were 
similar in terms of their total protein levels and maternal ages, but the pooled preeclampsia plasma 
sample contained approximately 50% less PZP than the control and the mean gestational ages of the 
two cohorts differed by several weeks (Table 1). The data show that after 500 h of incubation the turbidity 
of the PZP-deficient pooled plasma sample from preeclamptic women had increased significantly, but no 
significant change was detected in the pooled sample from matched controls (Fig. 5C). Combined 
together these results support the conclusion that similar to other extracellular chaperones (15), PZP 
stabilises a range of misfolded protein clients including aggregation-prone peptides and denatured 
proteins.  
 
Endogenous proteases do not induce the formation of tetrameric PZP in blood plasma in situ 
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As previously mentioned, demonstration of the protease-trapping action of PZP has currently been limited 
to studies involving purified protein in vitro (23-27). In the present study, to evaluate the protease-trapping 
action of purified PZP versus PZP in plasma, the effects of incubation with chymotrypsin were 
determined. When purified PZP was co-incubated with chymotrypsin (molecular weight 25 kDa), a small 
amount of PZP was found to form a high molecular weight species (Fig. 6A). This result supports a 
proposed model for protease trapping in which two PZP molecules form a tetrameric complex around the 
covalently-bound protease (23). Interestingly, when human pregnancy plasma was incubated at 37°C for 
45 min and assessed by native Western blot analysis there was negligible evidence that a similar high 
molecular weight PZP species is formed under these conditions in situ (Fig. 6Bi). Moreover, 
supplementation of the plasma with 1 µM chymotrypsin had no observable effect on the migration of 
PZP. In the same plasma samples, native α2M was converted to an electrophoretically fast form (similar 
to α2M*; Fig 1B) and the effect was greater when the plasma was supplemented with chymotrypsin (Fig. 
6Bii). The latter behaviour is consistent with protease trapping by α2M, which causes the α2M tetramer to 
become compact (24). In contrast to the anti-α2M antibody that was found to bind strongly to protease-
bound electrophoretically fast α2M (Fig. 6Bii), the anti-PZP polyclonal antibody used in this study bound 
preferentially to the native PZP dimer (SI Appendix Fig. S3). Given that the putative PZP-protease 
complexes were not detected in situ following the addition of high levels of chymotrypsin (Fig 6B), 
densitometry was used to confirm that the levels of native PZP in plasma were not detectably reduced 
following the addition of chymotrypsin (Fig. 6C).  
 
PZP is predominantly absent from extracellular Aβ deposits in preeclampsia 
We have previously reported the presence of amyloid precursor protein (APP) proteoforms in amyloid-
like plaques in placentas from women with severe preeclampsia comorbid with fetal growth restriction 
(8). To identify if there is potential for PZP to act as a local chaperone in the placenta we performed 
immunohistochemical analysis of well-characterized cases of preterm birth with and without 
preeclampsia and/or fetal growth restriction; relevant clinical information pertaining to these samples is 
provided in SI Appendix Table S1. Extravillous trophoblasts (EVTs) in the basal plate, placental septa 
and cell islands stained strongly for PZP in all clinical scenarios, but several patterns emerged relative 
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to histological changes in placenta that are commonly associated with preeclampsia (Fig. 7A-C). In the 
maternal floor of the placenta of idiopathic preterm birth, PZP-positive EVTs were seen scattered (Fig. 
7A); in preeclampsia, however, they appeared to migrate around avascular villi (Fig. 7B&C) thus 
contributing to the characteristic “lacy appearance” of confluent placental islands (Fig. 7D) classically 
described in preeclamptic placentas populated by increased numbers of proliferating migratory EVTs 
(Stanek 2011, Moser 2011). Staining of serial sections supported the notion that these cells also harbour 
Aβ (Fig. 7E) as well as cytokeratin-7 (Fig. 7F) thus confirming their trophoblast phenotype.  
 
To determine whether or not PZP co-localises with Aβ in insoluble plaques in vivo, we performed double 
immunofluorescence studies with a particular focus on confluent placental islands (Fig 7H-N). EVTs that 
were stained intensely red for PZP were seen surrounding acellular areas in vicinity to extracellular green 
fluorescent Aβ deposits (orange arrows, Fig. 7H) and isolated EVTs, which appeared morphologically 
necrotic (white arrows). The vicinity between extracellular Aβ and dying EVTs was better appreciated 
using confocal imaging (Fig. 7I). Upon z-stack reconstruction, zones of merged yellow fluorescence 
suggested that a small amount of PZP was co-deposited with Aβ in plaques (Fig. 7J, blue arrows), 
although, it is clear that deposited Aβ is not predominantly bound to PZP. Further analysis of the 
intracellular location of PZP and Aβ is presented in SI Appendix Fig. S4.  
 
Discussion 
Consistent with the  functions of PZP having systemic importance throughout pregnancy, PZP levels are 
dramatically elevated in blood plasma from an early stage during gestation (20). The latter is a relevant 
observation, as the accumulation of misfolded proteins is not isolated to the placenta in preeclampsia, 
but has been measured in serum and urine (8, 9, 12). The results of this study demonstrate that PZP 
stabilises Aβ and other misfolded client proteins more efficiently than the constitutively abundant α2M 
tetramer, which has received substantial attention for its role as an extracellular chaperone (reviewed 
in(15). Given the extent to which PZP is upregulated in mid- to late-pregnancy, it is conceivable that PZP 
is a major regulator of extracellular proteostasis during gestation. However, it is probable that PZP does 
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not act alone to stabilise misfolded proteins in maternal fluids (e.g. modest chaperone-like activity has 
been reported for the pregnancy-associated SERPINB2 (39)). Thus, the results generated from the 
current study provide an important first step towards understanding how the maternal body adapts to 
handle the unique challenges to extracellular proteostasis during pregnancy.  
 
A model for the related chaperone mechanisms of PZP and α2M 
Our data show that native PZP (a dimer) exposes more hydrophobicity to solution than native tetrameric 
α2M, and binds to Aβ monomers and/or small Aβ oligomers that do not form stable complexes with native 
α2M. Therefore, the results of this study support a model in which binding sites for Aβ (and other misfolded 
proteins) are present on constitutively exposed hydrophobic surfaces of the native PZP dimer that, in the 
closely related native α2M tetramer, are located at the normally buried hydrophobic interface between 
pairs of disulphide-linked α2M dimers (40, 41). Consistent with this model, we have previously shown that 
hypochlorite-induced dissociation of the native α2M tetramer enhances its binding to Aβ (29). Although 
the precise binding sites for  Aβ on PZP are not yet known, a previously reported binding site for Aβ on 
α2M (centred at amino acids 1314-1365), but sterically shielded in the native α2M tetramer (42)) shares 
85.7% sequence identity with the corresponding region of PZP (SI Appendix Fig. S5).  
 
The available data suggests that native α2M can be rapidly induced to become PZP-like via hypochlorite-
induced dissociation (29), which potentially acts as an important first line of defence that transiently 
increases αM-mediated chaperone activity during severe inflammation. Considering that elevated 
myeloperoxidase levels have been reported in preeclampsia (43), it is plausible that hypochlorite-
modified α2M is transiently generated during an advanced stage of the syndrome that corresponds with 
severe inflammatory processes. Further studies to identify the precise conformations of hypochlorite-
modified α2M that are generated during inflammation and to define their relative abundance are needed 
in order to appreciate fully the importance of this process in vivo. Given the highly multifunctional nature 
of α2M, the current study paves the way for evaluating whether or not other activities that are enhanced 
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by dissociation of the native α2M tetramer, such as binding to cytokines (32), are also important roles for 
PZP.   
 
The chaperone activity of PZP potentially influences pregnancy-associated and pregnancy-
independent protein misfolding 
Interest in the role of α2M in Alzheimer’s disease spans several decades with a number of early genetic 
studies reporting an association between mutations in α2M and the risk of disease (44-47). This 
association has not, however, been confirmed by more recent genome-wide association studies 
(reviewed in(48), which suggests that additional factors such as post-translational modification could be 
important. Interestingly, elevated levels in serum of α2M or PZP are reportedly associated with pre-
symptomatic Alzheimer’s disease in men and women, respectively (49, 50). Furthermore, both α2M and 
PZP are found to be co-localised with Aβ in the brain in Alzheimer’s disease (51, 52). It is not yet known 
if the elevated levels of PZP measured in women with pre-symptomatic Alzheimer’s disease are the 
consequence of a general innate immune system response, since PZP levels are reported to be elevated 
in several other inflammatory states including rheumatoid arthritis (53), Behcet’s syndrome (54), psoriasis 
(55, 56) Chagas disease (57) and viral infection (58, 59). Nevertheless, the available data strongly 
suggest that both α2M and PZP are likely to participate in Aβ homeostasis in vivo. It remains to be 
determined whether or not their roles are overlapping or discrete. 
 
Previous studies have reported that that low levels of maternal plasma PZP are associated with 
spontaneous preterm birth (60) and an increased risk of preeclampsia (61-63). On the other hand, 
opposing and inconclusive data have also been reported regarding a negative correlation between 
maternal plasma PZP levels and preeclampsia (64, 65). As such, there is a need to re-evaluate this 
association with greater consideration of both the clinical spectrum of preeclampsia (66) and the accurate 
quantification of PZP independently of the closely related α2M, which even modern proteomic methods 
have struggled to distinguish from each other (65). Although detailed analysis of the chaperone activity 
of PZP in pregnancy plasma in situ is outside of the scope of the current study, our results provide the 
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first indication that PZP-deficiency could contribute to the accumulation of misfolded proteins in 
preeclampsia. Consistent with this idea, high levels of plasma PZP are associated with pregnancy-
associated remission of rheumatoid arthritis (67), a condition exacerbated by the accumulation of 
damaged proteins in the synovial fluid of inflamed joints (68, 69). However, our inability to assay a large 
number of samples from individual women with preeclampsia and matched controls is a limitation of this 
study. Additionally, preeclampsia is a complex multifactorial syndrome and previously reported 
immunomodulatory activities (17, 70-72) or currently undescribed functions of PZP that mirror the 
multifunctional nature of α2M could also be important (reviewed in(73).   
 
It has previously been reported that microglia that are immunoreactive for PZP co-localise with Aβ 
deposits in the brain in Alzheimer’s disease (51).  The pathobiological relevance of PZP expression at 
sites of Aβ deposition, however, remains unclear. Given that our data demonstrate that PZP is found in 
extravillous trophoblasts in cell islands adjacent to placental Aβ plaques, there is a need to establish the 
relative contributions of fetal and maternal plasma PZP to normal placental function including Aβ 
homeostasis. The observation that PZP is largely excluded from Aβ plaques in the placenta supports our 
hypothesis that PZP normally forms soluble complexes with Aβ that are subsequently taken up by cells 
and cleared. Co-deposition of PZP with Aβ in the placenta in preeclampisa could indicate that the 
chaperone activity of PZP or receptors responsible for its clearance, are overwhelmed or dysfunctional 
in the syndrome. The intriguing cytoplasmic and nuclear localization of PZP observed in the placenta 
suggests that this protein might also have currently undescribed intracellular roles (SI Appendix Fig. S4). 
Using STRING analysis (74), nuclear importins 7 and 8 are predicted to bind to PZP with medium 
confidence, although further studies are needed to examine this possibility.   
 
 PZP is not a major in situ inhibitor of proteases in pregnancy plasma 
The emergence of the α2M tetramer from a dimeric precursor appears to have been driven by 
evolutionary pressures (75). However, it is clear that in many mammals, including humans, dimeric PZP 
has relevance in pregnancy and in non-pregnancy-associated inflammatory states. Although α2M and 
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PZP share extensive sequence identity, such identity does not occur in the protease bait region (21), 
which explains why the broad spectrum protease inhibitory activity of α2M is not shared by PZP. 
Consistent with the results of several other in vitro studies, the results generated here using human 
pregnancy plasma in situ, support the conclusion that α2M is much more proficient at trapping abundant 
endogenous plasma proteases compared to PZP (23-25). Given that protease-trapping is currently the 
only biologically-relevant mechanism known to expose the LRP1 binding site on PZP (35) it is plausible 
that this reaction occurs in vivo. If it does occur, however, the identities of the major protease substrates 
are currently unclear. Proteases from the fibrinolytic and coagulation cascade have been proposed as 
potential targets of PZP (27), but conflicting results have also been presented (76). When the protease 
specificity of the PZP bait region is analysed using the bioinformatics tool PROSPER, cleavage sites are 
predicted for both metalloproteases matrixmetallopeptidase-2 and -9 and for serine proteases elastase-
2 and cathepsin G (77). Limited in vitro data also suggest that metalloproteases and intracellular 
proteases, including elastase, might be endogenous substrates for PZP (24, 26). On the other hand, 
given that all of these proposed protease substrates are more efficiently trapped by the α2M tetramer 
than by the PZP dimer (24, 26), it is difficult to imagine that the upregulation of PZP in pregnancy is 
exclusively linked to its protease-trapping function.  
 
Pregnancy-associated maternal adaptations contribute to proteostasis 
Research into the extracellular quality control of protein folding has primarily been driven by the 
knowledge that misfolded proteins accumulate in a large number of age-related disorders such as 
Alzheimer’s disease, arthritis, atherosclerosis and macular degeneration. The pregnancy-associated 
syndrome preeclampsia clearly stands apart from these conditions. On the other hand, mature age and 
pregnancy can both be viewed as life stages that involve chronically elevated physiological stresses than 
contribute to protein misfolding (2, 14). In addition to the accumulation of misfolded protein aggregates, 
there are numerous similarities between pre-eclampsia and many age-related protein misfolding 
disorders including strong inflammatory pathology and vascular dysfunction (78, 79). Furthermore, it has 
been shown that premature placental ageing underlies early onset preeclampsia (80) and it has been 
proposed that the placenta is a tractable model for aging human tissue (81). Interestingly, recent data 
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suggest that, after preeclampsia, women have a fourfold increased risk of death from Alzheimer’s disease 
than the general female population (82). While potentially explained by increased cardiovascular and 
cerebrovascular disease rates in this group, common pathophysiologies related to protein misfolding 
might also play a role. Therefore, it is tempting to speculate that a greater understanding of the maternal 
adaptations for controlling protein misfolding in pregnancy could help us to understand better the 
phenomenon of age-related protein misfolding and hence to contribute to the development of novel 
therapeutic strategies.  
 
Materials and Methods 
All chemicals and buffer salts were obtained from Sigma-Aldrich, unless otherwise stated.  
PZP and α2M purification from human plasma 
Heparinised human pregnancy plasma was obtained from donors as approved by either the 
Cambridgeshire 2 Research Ethics Committee (reference number 07/ H0308/163) or the joint UOW & 
ISLHD Health and Medical Human Research Ethics Committee (application numbers 2013/377 and 
2016/1016) and stored ≤ -20°C until use.  All participants provided written informed consent. Donated 
blood samples were deidentified prior to use in this study as specified in the relevant approved ethics 
applications. This included donations from women with no known pregnancy complication (control) or 
women diagnosed with preeclampsia. PZP was subsequently purified from control pregnancy plasma as 
described in (33).  
 
Native α2M was purified from normal (i.e. non-pregnant) blood plasma without amendment as described 
in (83). This collection was approved by the joint UOW & ISLHD Health and Medical Human 
Research Ethics Committee (application number HE02/080). Transformed α2M was generated by 
incubating 1.4 µM native α2M with 400 mM NH4Cl in phosphate buffered saline, pH 7.4 (PBS) overnight 
at room temperature, followed by extensive dialysis against PBS. Hypochlorite-modified α2M was 
generated by incubating 0.55 µM α2M with 120 µM NaOCl in PBS overnight at ambient room temperature, 
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followed by extensive dialysis against PBS to remove unreacted NaOCl. Hypochlorite-modified α2M 
dimers were purified from residual α2M tetramer via Superose 6 10/300 GL size exclusion 
chromatography (SEC).  
 
Electrophoresis and Western Blot analyses 
Proteins were subjected to native gel electrophoresis using NuPAGE Novex 3–8% Tris-acetate gels and 
Novex Tris-glycine native buffers (Life Technologies). Denaturing gel electrophoresis was performed 
using NuPAGE Novex 4–12% Bis-Tris gels and NuPAGE Mes SDS running buffer. Where specified, 
samples were reduced by treatment with β-mercaptoethanol. Gels were stained using Instant Blue stain 
(Sigma-Aldrich). In experiments involving Hilyte-labelled Aβ1-42, the migration of the fluorescently labelled 
peptide was determined using a Typhoon Trio Imager (GE Healthcare). 
For Western blot analysis proteins were subjected to electrophoresis as described above and transferred 
to nitrocellulose membrane. After blocking overnight at 4 °C in skim milk solution [5% (wt/vol) skim milk 
powder in PBS], the membranes were incubated with the relevant antibodies/streptavidin conjugates 
diluted in skim milk solution (1 h at 37°C). Blots were imaged with an Amersham 600 imager (GE 
Healthcare) using enhanced chemiluminescence. PZP was detected using affinity-purified polyclonal 
antibody (GeneTex), α2M was detected using monoclonal antibody 2N1/10 (Bio-Rad) or polyclonal 
antibody (Dako) and Aβ1–42 was detected using monoclonal antibody W02 supernatant.  
 
Thioflavin T (ThT) assays 
Aβ1–42 (5 µM; Anaspec) was incubated at 32°C with shaking in PBS containing ThT (25 µM) in the 
presence or absence of native α2M, PZP or hypochlorite-modified α2M dimer (pre-treated using NaOCl 
and purified from residual tetramers by SEC as described above). The ThT fluorescence of the samples 
was continuously monitored using a FLUOstar OPTIMA platereader (BMG Labtech Ltd.) with excitation 
and emission wavelengths of 440 nm and 480 nm (slit widths of 10 nm), respectively. At the conclusion 
of the assay, following brief centrifugation to pellet insoluble material (5 min at 21,000 xg), the relative 
amount of soluble Aβ1–42 in each sample was measured by subjecting 20 µl of the supernatant to native 
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Western blot analysis and performing densitometry using ImageJ software. The density of soluble Aβ1–
42 in samples containing dimeric αMs is presented relative to soluble Aβ1–42 in samples containing native 
tetrameric α2M. 
 
4,4-Dianilino-1,1-binaphthyl-5,5-disulfonic acid (bisANS) assay 
For bisANS analyses, 170 nM native α2M tetramer, native PZP dimer or hypochlorite-modified α2M dimer 
were incubated with 10 µM bisANS in PBS for 5 min at ambient room temperature before the 
fluorescence was measured on a FLUOstar OPTIMAplate reader with excitation and emission 
wavelengths of 360nm and 490nm (slit widths of ±10 nm), respectively. All reported values are corrected 
for the background fluorescence of bisANS in PBS. 
 
Transmission Electron Microscopy 
Aβ1–42 was incubated in the presence or absence of native α2M, PZP or oxidized α2M dimer as 
described for ThT assays. The samples were then applied to 400 mesh carbon film copper grids (Agar 
Scientific) and imaged on an FEI Tecnai G2 transmission electron microscope (CAIC, University of 
Cambridge, Cambridge, UK). Images were analysed using the SIS Megaview II Image Capture system 
(Olympus, Tokyo, Japan).  
 
Biotin-Streptavidin Pull-Down Assays 
Binding of PZP to commercially prepared biotinylated Aβ1–42 (bAβ1–42; Cambridge Bioscience) was 
performed following their co-incubation at a 1:10 molar ratio of PZP to bAβ1–42 in PBS for 10 min at 
ambient room temperature. Biotin-streptavidin pull-down assays were performed using Dynabeads My 
One Streptavidin C1 according to the manufacturer’s instructions (Life Technologies).  
 
Turbidity assays 
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CS (1 µM in PBS; Sigma-Aldrich) was incubated in the presence or absence of native PZP or native α2M 
at 43 °C in a FLUOstar OPTIMA plate reader while the absorbance at 595 nm was continuously 
monitored. For clarity kinetic curves and analysis of end-point absorbance values are presented in 
separate charts. In other experiments CPK (5 µM in PBS; Sigma-Aldrich) was incubated in the presence 
or absence of ECAM, PZP or α2M at 55 °C while the absorbance at 595 nm was continuously monitored 
as described above. Recombinant ECAM was purified as described in (84). The plasmid used for 
purifying ECAM was a gift from Andréa Dessen (University Grenoble-Alpes, France). 
Using methods similar to previous studies we assessed the aggregation of protein in human plasma in 
situ (37, 38). Briefly, heparinised blood plasma samples from individuals exhibiting uncomplicated 
pregnancy (n = 6) or preeclampsia (n = 9) were pooled. Total protein was estimated using bicinchoninic 
acid (BCA) assay and the plasma was supplemented with 0.01% NaN3 to prevent microbial growth during 
the assay. PZP quantification was performed using an R & D Systems ELISA kit according to the 
manufacturer’s instructions (in vitro Technologies). Four 70 µL aliquots of pooled plasma from each 
cohort were dispensed into a Griener 384-well plate and incubated at 38°C for 500 h with periodic 
agitation in a FLUOstar OPTIMA plate reader (BMG Labtech Ltd.) The absorbance at 595 nm was 
measured as an indicator of plasma turbidity.  
 
Protease trapping assays 
The protease trapping activity of purified PZP was examined after incubation with chymotrypsin at a 2:1 
molar ratio of PZP-to-chymotrypsin for 30 min at 37°C by subjecting the proteins to separation using 
native gel electrophoresis. Under these conditions protease trapping is detected by the formation of a 
high molecular weight complex consisting of two molecules of PZP and one molecule of protease (23). 
To examine the ability of PZP to trap proteases in heparinised human pregnancy plasma in situ, plasma 
was incubated at 37°C for 45 min in the presence or absence of 1 µM chymotrypsin. An additional sample 
(not supplemented with chymotrypsin) was held on ice top limit the activity of endogenous plasma 
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protease. Following separation using 3-8% Tris-acetate gels, proteins were transferred to PVDF 
membranes and probed for PZP or α2M (as described in Electrophoresis and Western Blot analyses). 
 
Placental immunohistochemistry and immunofluorescence  
We analysed placental tissues of women with medically indicated delivery in the context of early-onset 
severe preeclampsia (sPE, n=11, gestational age (GA) at delivery (mean ± standard deviation): 30±3 
weeks). Tissues from a group of women with spontaneous idiopathic preterm birth at a similar gestational 
age (iPTB, n=8, GA: 30±2, P=0.453) served as the best possible control. All women were delivered at 
Yale-New Haven Hospital and provided signed informed consent under protocols approved by the 
Human Investigation Committee of Yale University. Donated tissues were deidentified prior to use in this 
study as specified in the relevant approved ethics application. Within minutes of the time of delivery of 
the placenta, a full thickness biopsy was retrieved from the central portion of the placenta and fixed in 
formalin and embedded in paraffin. Five µm serial sections were deparaffinized in xylene and rehydrated 
with graded ethanol to potassium phosphate-buffered saline solution, pH 7.2. Following antigen retrieval 
with citrate buffer, sections were pretreated with 1% hydrogen peroxide for 15 min followed by incubation 
for 1 h at room temperature with 5% donkey serum (Jackson ImmunoResearch Laboratories, West 
Grove, PA). Sections were then incubated overnight at 4°C with primary antibodies followed by incubation 
for 1 h at room temperature with biotinylated donkey anti-rabbit or anti-mouse IgG (1:600, Jackson 
ImmunoResearch Laboratories) as appropriate. Signal amplification and detection was performed with 
avidin-biotin (VECTASTAIN® Elite ABC, Vector Laboratories, Burlingame, CA) using Vector NovaRed 
as peroxidase substrate. Sections exposed to non-immune IgG served as negative control. The following 
primary antibodies were used: polyclonal anti-PZP (1:100, GeneTex, Irvine, CA), monoclonal anti-Aβ 
antibodies (clone WO2, Millipore, Temecula, CA), monoclonal anti-cytokeratin-7 (1:100, InVitrogen, 
Camarillo, CA) and monoclonal anti-HLA-G (1:100, clone 4H80, Abcam, Cambridge, MA). 
To co-localize PZP with Aβ we performed double immunofluorescence on select tissues. After 
deparafinization and antigen retrieval with citrate buffer the slides were blocked with 100mM glycine 
followed by 10% goat serum for 1 h at room temperature. Slides were further incubated overnight at 4C 
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with the cocktail of primary antibodies anti-PZP, (1:100) and anti-Abeta (clone W02, 1:250). Following 
washing slides were exposed for 1 h at room temperature to a secondary antibody cocktail contained 
2µg/mL of goat anti-mouse IgG conjugated to Alexa Fluor 488, and 2µg/mL of goat-anti-rabbit IgG 
conjugated to Alexa Fluor 594 plus 1µg/mL DAPI. Slides were mounted with ProLong Gold Antifade 
medium and images captured using a Zeiss LSM700 confocal laser-scanning microscope (Zeiss, 
Thornwood, NY). 
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Figure legends 
 
Figure 1. Western blot and native PAGE analyses of PZP in human pregnancy plasma and 
following purification. (A) Image of a Western blot showing the migration of PZP pre-and post-
purification from pregnancy plasma, after separation using a 3-8% Tris-acetate native gel. The position 
of PZP is indicated with an arrow. A corresponding amount of purified α2M was not detected (final lane). 
(B) Image of a 3-8% Tris-acetate native gel showing the migration of purified PZP, α2M, transformed α2M  
(α2M* ;an electrophoretically fast tetramer) and hypochlorite-modified α2M (α2M ox). The positions of αM 
tetramers and dimers are indicated. (C) Images of Western blots showing the relative PZP levels in 8 
individual pregnant women at 36 weeks gestation. Pregnancy plasma (1 µL) was separated using a 3-
8% Tris-acetate native gel and proteins were transferred to a nitrocellulose  membrane. The blot was 
initially probed using an anti-PZP antibody and then the same blot was re-probed using an anti-α2M 
antibody. Images show the major bands detected and are cropped and realigned to assist comparison 
of the respective levels of PZP and α2M present. (D)  Densitometry analysis of Western blots showing 
the relative levels of PZP and α2M in 14 individual women at 36 weeks of pregnancy. R2 is calculated 
using Pearson's correlation co-efficient.  
 
Figure 2. Effects of α2M tetramer, α2M dimer and PZP on the aggregation of Aβ1-42 as assessed by 
ThT assay. (A) Aβ1-42 (5 µM) was incubated with 25 µM ThT in PBS at 32°C with constant shaking. Aβ1-
42 was also co-incubated with either native α2M, PZP or SEC purified α2M dimer at molar ratios of  (i) 1:80; 
(ii) 1:40 or (iii) 1:20 (αM-to-Aβ1-42 ) under the same conditions. The results shown are the average ThT 
fluorescence (Ex. 440 nm Em. 480 nm; n = 4 ± SEM) in arbitrary fluorescence units (AFU) and are 
representative of three independent experiments. The symbol * denotes significantly reduced Th-T 
fluorescence compared to Aβ1-42  alone and corresponding samples co-incubated with native α2M as 
assessed at the end of the assay (Tukey HSD, P < 0.05) and  ** denotes significantly reduced ThT 
fluorescence compared to compared to Aβ1-42  alone as assessed at the end of the assay (Tukey HSD, 
P < 0.05). (B) Corresponding bisANS analysis of αM preparations as described in (A). The data are the 
mean bisANS fluorescence (Ex. 360 ± 10 and Em. 490 ± 10 nm) of triplicate samples ± SEM and are 
corrected for the background fluorescence * Denotes significantly higher bisANS fluorescence of PZP 
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compared to native α2M (Tukey HSD, P < 0.01) and ** Denotes significantly higher bisANS fluorescence 
of dimeric α2M compared to native α2M and PZP (Tukey HSD, P < 0.01).  (C) The effects of native α2M 
and PZP on amyloid formation were examined using an αM subunit-to-Aβ1-42 ratio of 1:20, under these 
conditions the mass of α2M and PZP used in the assay are equivalent. The results shown are the average 
ThT fluorescence (arbitrary fluorescence units, AFU) of triplicate samples and are representative of three 
independent experiments. Error bars are the SEM. The symbol * denotes significantly reduced ThT 
fluorescence compared to Aβ1-42  alone and corresponding samples co-incubated with native α2M as 
assessed at the end of the assay (Tukey HSD, P < 0.05).  
 
Figure 3. TEM images of Aβ1-42  after co-incubation with α2M tetramer, α2M dimer or PZP and 
corresponding measurements of soluble Aβ1-42 .Aβ1-42 (5 µM) was incubated ± native α2M, PZP or 
SEC purified α2M dimer at a molar ratio of 1:20 (αM-to-Aβ1-42 ) at 32°C with constant shaking for 
approximately 15 h. Samples of the protein solutions were snap frozen in liquid nitrogen before analysis 
by TEM. Scale bar represents 100 nm. (B) After incubation as described in (A) insoluble Aβ1-42 was 
removed by centrifugation and soluble Aβ1-42  was quantified by densitometry following Western Blot 
analysis (n=3 ± SEM). The density of soluble Aβ1–42 in samples containing dimeric αMs (grey) is 
presented relative to soluble Aβ1–42 in samples containing native tetrameric α2M (black). N.D. = not 
detected, N.S. = not significantly different (Tukey HSD; P > 0.05) 
 
Figure 4.  αM-Aβ1-42 complexes detected by native PAGE  and biotin-streptavidin pull-down assay. 
(A) (i) Fluorescence image of a native PAGE gel showing the migration of Hilyte fluor 488 labelled-Aβ1–
42 after incubation alone or with αMs at a 1:10 molar ratio of αM:Aβ1–42. α2M ox and α2M ox2 denote α2M 
pre-treated with 25 µM and 100 µM NaOCl, respectively, followed by dialysis to remove unreacted 
NaOCl. All samples were incubated for 30 min at ambient room temperature. (ii) Following fluorescence 
imaging, the gel was stained with instant blue and re-imaged to determine the position of all proteins.  
(B) Image of a Western blot detecting PZP recovered by biotin-streptavidin pull-down assay after 
incubation in the presence (+) or absence (-) of biotinylated Aβ1–42  for 30 min at RT.  Samples were 
incubated at a molar ratio of PZP:Aβ1–42 = 1:10 and were subjected to denaturing gel electrophoresis 
under reducing conditions prior to Western blot analysis. Under these conditions PZP dimer migrates as 
a 180 kDa monomer. The positions of molecular mass markers (Mr) are shown in kDa.  
 
Figure 5. Effect of αMs on the heat-induced aggregation of CS. (A) CS at 1 μM was incubated at 43 
°C ± PZP or α2M. The molar ratios of αM:CS used are shown. Turbidity was monitored using absorbance 
at 595 nm. The data shown in (i) are the mean of triplicate samples and are representative of two 
independent experiments. For clarity the mean absorbance at 595 nm (A595 nm) at the end-point of the 
assay including error bars is provided in (ii) (n=3 ± SEM). The symbol * denotes significantly reduced 
turbidity compared to the control sample containing CS alone (black bar) (Tukey HSD, P < 0.05) and ** 
denotes significantly reduced turbidity compared to the sample containing CS alone and the sample 
containing a corresponding amount of α2M (shaded area) (Tukey HSD, P < 0.05). (B) Turbidity assay 
showing CPK (5 μM) incubated at 55°C in PBS ± ECAM, PZP or α2M. The molar ratio of αM:CPK was 
1:5. Turbidity was monitored using absorbance at 595 nm. The data shown are individual measurements 
and are representative of two independent experiments. (C) Pooled plasma from individuals exhibiting 
normal uncomplicated pregnancy (control) or preeclampsia (see Table 1) was incubated at 38°C for 500 
h and routinely agitated. The turbidity was assessed using A595 nm. A bar chart displaying the mean 
A595 nm is shown (n = 4, ± SEM) and is representative of two independent experiments. The symbol † 
denotes significantly increased A595 nm at 500 h compared to 0 h (Student’s t-test, p < 0.05) 
 
Figure 6. αM-protease complex formation in vitro and in situ. (A) Image of a native gel showing the 
migration of purified native PZP and PZP-protease complexes. Putative PZP-protease complexes were 
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generated by pre-incubation with chymotrypsin (chym) at a 2:1 molar ratio of PZP-to-chym for 30 min at 
37°C. (B) Native Western blot analysis showing putative αM-protease complexes in human pregnancy 
plasma. Heparanised human pregnancy plasma was incubated at 37°C for 45 min in the presence or 
absence of 1 µM chym. An additional sample was held at 4°C on ice for the same period (control). Blots 
probed for (i) PZP or (ii) α2M are from the same experiment. The expected position of the PZP-chym and 
α2M-chym complexes are indicated. (C) The band corresponding to the native PZP dimer was quantified 
using densitometry in pregnancy plasma treated as described in (B). The graph shows the mean PZP 
level relative to the control (n = 5 independent experiments ± SD). 
 
Figure 7. Immunolocalization of PZP in the human preterm placenta. Representative micrographs 
of the maternal floor of the placenta at the interface between basal plate (bp) and villous tissue (vt) in (A) 
iPTB = idiopathic pre-term birth (gestational age matched control); (B) sPE = severe preeclampsia; and 
(C) sPE+FGR = fetal growth restriction. (D-G) Serial sections of placenta from a woman with early onset 
sPE+FGR  showing a confluent placenta cell island (cpci) at the interface between villous tissue and the 
chorionic plate (cp). The sections have been immunostained for (D) PZP, (E) Aβ and (F) cytokeratin-7 
(CK7). (G) Negative control slide exposed to non-immune rabbit IgG. Vector Red was used as peroxidase 
substrate and hematoxylin as counterstain. The insets show at higher magnification regions populated 
by extravillous trophoblasts which are arranged in an orderly manner in iPTB but border many avascular 
ghost villi in preeclampsia (black arrows). Black scale bar represents 100 µm. (H-J) Confocal microscopy 
of placenta from two women with sPE+FGR double immunostained for PZP (red fluorescence), Aβ (green 
fluorescence). DAPI was used as nuclear counterstain. (H) A confluent placental cell island populated by 
PZP-positive extravillous trophoblasts and plaque-like deposits of extracellular Aβ (orange arrows). Dead 
or dying cells in vicinity of Aβ deposits (white arrows). Trophoblasts staining positive for PZP surround 
many avascular ghost villi (white asterisk). (I) Higher magnification of the area in H framed in continuous 
line with (J) additional magnification and z-stack 3D reconstruction of the area framed in H. The irregular 
cellular shape and loss of nuclear DAPI staining suggest cell death. The blue arrows point to intensely 
yellow fluorescence generated by proximity of PZP and Aβ epitopes. White scale bar represents 50 µm. 
 
